Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Triple Therapy for COPD Linked With Higher Pneumonia Hospitalization Risk

Key clinical point: In chronic obstructive pulmonary disorder (COPD), triple therapy of long-acting muscarinic antagonist (LAMA), long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) is as effective but linked to more severe pneumonia than LAMA-LABA therapy without ICS.

Major finding: Patients on LAMA-LABA-ICS vs. LAMA-LABA therapy were more likely to be hospitalized with severe pneumonia. (Adjusted hazard ratio, 1.46; 95% Confidence interval, 1.03-2.06, P = .27).

Study details: One-year monitoring of 6,921 patients with COPD who started LAMA-LABA-ICS vs. 1,932 who started LAMA-LABA.

Disclosures: The Canadian Institutes of Health Research, Canadian Foundation for Innovation and Boehringer-Ingelheim funded the study in part. One author reports research grants (Boehringer Ingelheim and Novartis) and advisory board/speaker relationships with AstraZeneca, Boehringer-Ingelheim, and Novartis. The other authors report no disclosures.

Citation:

Suissa S et al. Chest. 2019 Nov 21